Neurocrine Biosciences shares drop as trial failures may ‘stunt momentum,’ analysts say
November 10, 2023 at 08:59 AM EST
Company will halt development of experimental depression treatment
|
||||||||||||
|
||||||||||||
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map |